ClinicalTrials HQ

MedSIR

MedSIR

Explore linked clinical trials.

19 results ยท Page 1 of 1

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationNeoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22026-09-24NCT05708235
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisBrain Metastases, Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 22026-09-09NCT06315010
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcomaRecruitingPhase 1 / Phase 22026-08-31NCT07460986
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast CancerRecruitingPhase 32026-08-24NCT06382948
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeAdvanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast CarcinomaRecruitingPhase 22026-07-30NCT06486883
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.Advanced Breast Cancer; HER2 Mutation; Hormone Receptor Positive / HER2-negative Breast CancerNot yet recruitingPhase 22026-06-01NCT07619066
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingPhase 22026-05-29NCT07195227
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain MetastasesNeoplasms by Site, Skin and Connective Tissue Diseases, brain disorder, breast cancer, breast disorder, breast neoplasm, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder, skin disorderActive, not recruitingPhase 22026-05-08NCT06048718
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaActive, not recruitingPhase 22026-05-08NCT05498896
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22026-04-29NCT06172127
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22026-04-29NCT04733118
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderNot yet recruitingPhase 1 / Phase 22026-04-23NCT07494448
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic ProgressionAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorderRecruitingPhase 22026-04-22NCT06180356
A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCERBiliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, neoplasmNot yet recruitingNot stated2026-04-07NCT07515950
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22026-03-10NCT05810870
Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderNot yet recruitingPhase 22026-01-28NCT07367178
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast CancerAdvanced Breast CancerActive, not recruitingPhase 1 / Phase 22025-12-05NCT06612203
Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain MetastasesHER2-positive Breast Cancer; Solid TumorsNot yet recruitingPhase 22025-11-14NCT07178938
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22025-04-23NCT03161353